8 results
Primary: To determine whether ofatumumab 3, 30 or 60 milligrams (mg) given subcutaneously (SQ), reduces the cumulative number of new T1 GdE brain lesions over a period of 12 weeks, as compared with placebo.Secondary: Cumulative number of new T1 GdE…
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment versus no further treatment after remission induction in subjects with relapsed CLL.Secondary objectives are to evaluate clinical benefit,…
To determine the efficacy of two dose regimens of HuMax-CD20 in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapy or to rituximab given as maintenance treatment.
Primary: To evaluate the efficacy and safety of HuMax-CD20 in patients with B-cell Chronic Lymphocytic Leukemia (B-CLL) who have failed fludarabine and alemtuzumabSecondary: To determine the host immune response to HuMax-CD20To determine the…
The primary objective of this study is to evaluate the impact of carbon dioxide field flooding on the quantitative intraoperative microembolic load of the brain during aortic arch surgery.A secondary objective is to evaluate any concomitant…
To demonstrate that ofatumumab is superior to teriflunomide in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in patients with relapsing MS
The aim of this study is to validate the accuracy of SNNS for the detection of tumor-positive LNs using lymphoscintigraphy with radioactive tracer and NIR with ICG in patients with early EAC with regional LN involvement (clinically staged as T1N1).
This study is designed to collect long-term safety, tolerability, effectiveness and health outcomes data in RMS patients.COVID-19 substudy:The purpose of this COVID-19 research sub-study is to determine the effects of the study treatment (ofatumumab…